About immunoprint
immunoprint is a immunohistochemistry based assay that measures the expression of seven proteins
Patients are allocated to two groups:
- Low risk means at low risk of relapse and death
- High risk means at high risk of relapse and death
immunoprint validation data across stages I-III
Clinical evidence
immunoprint
has been validated in patients with stage I-III melanoma.
Publications include:
-[1] Meyer et al. Eur. J. Cancer (2023)
-[2] Reschke et al., J. Cancer (2021)
-[3] Amaral et al., ASCO (2023)
